Evidence map›Paper›PMID 35164081›Full record

ArticleMolecules (Basel, Switzerland)2022

Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70.

Suzanne O'Connor, Yann-Vaï Le Bihan, Isaac M Westwood, Manjuan Liu, Oi Wei Mak, Gabriel Zazeri, Ana P R Povinelli, Alan M Jones, Rob van Montfort, Jóhannes Reynisson and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Suzanne O'ConnorCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0003-2569-0338
Yann-Vaï Le BihanCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0002-6850-9706
Isaac M WestwoodCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
Manjuan LiuCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
Oi Wei MakSchool of Pharmacy and Bioengineering, Keele University, Keele ST5 5BG, UK.
Gabriel ZazeriSchool of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.ORCID 0000-0001-9957-9697
Ana P R PovinelliSchool of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.ORCID 0000-0001-6282-5380
Alan M JonesSchool of Pharmacy, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.ORCID 0000-0002-3897-5626
Rob van MontfortCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.
Jóhannes ReynissonSchool of Pharmacy and Bioengineering, Keele University, Keele ST5 5BG, UK.ORCID 0000-0003-4174-9512
Ian CollinsCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0002-8143-8498
Institute of Cancer Research · GBInstituto de Biologia do Exército · BRAlbert Einstein College of Medicine · USKeele University · GBUniversity of Birmingham · GB

Funding

Cancer Research UK 22897Cancer Research UK C309/A11566
6 · The paper itself

Abstract

Heat Shock Protein 70s (HSP70s) are key molecular chaperones that are overexpressed in many cancers and often associated with metastasis and poor prognosis. It has proven difficult to develop ATP-competitive, drug-like small molecule inhibitors of HSP70s due to the flexible and hydrophilic nature of the HSP70 ATP-binding site and its high affinity for endogenous nucleotides. The aim of this study was to explore the potential for the inhibition of HSP70 through alternative binding sites using fragment-based approaches. A surface plasmon resonance (SPR) fragment screen designed to detect secondary binding sites in HSP70 led to the identification by X-ray crystallography of a cryptic binding site in the nucleotide-binding domain (NBD) of HSP70 adjacent to the ATP-binding site. Fragment binding was confirmed and characterized as ATP-competitive using SPR and ligand-observed NMR methods. Molecular dynamics simulations were applied to understand the interactions with the protein upon ligand binding, and local secondary structure changes consistent with interconversion between the observed crystal structures with and without the cryptic pocket were detected. A virtual high-throughput screen (vHTS) against the cryptic pocket was conducted, and five compounds with diverse chemical scaffolds were confirmed to bind to HSP70 with micromolar affinity by SPR. These results identified and characterized a new targetable site on HSP70. While targeting HSP70 remains challenging, the new site may provide opportunities to develop allosteric ATP-competitive inhibitors with differentiated physicochemical properties from current series.

Indexed as

Adenosine TriphosphateBinding SitesDrug DiscoveryHSP70 Heat-Shock ProteinsHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationProtein DomainsSmall Molecule LibrariesAdenosine TriphosphateHSP70 Heat-Shock ProteinsLigandsSmall Molecule Librariescryptic pocketfragment screenHSP70molecular dynamicsvirtual screen

Identifiers

PMID35164081
PMCPMC8839746
OpenAlexW4210638108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.